← Back to Search


Xenon MRI for Pulmonary Arterial Hypertension (Jupiter PH Trial)

Phase 2
Led By Sudarshan Rajagopal, MD, PhD
Research Sponsored by Bastiaan Driehuys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH
Diagnosis of precapillary PH in the setting of Group 1 (PAH), 3 (PH due to chronic lung disease), 4 (PH due to pulmonary artery obstructions), or 5 (PH due to miscellaneous causes)
Must not have
Sickle cell anemia
Liver disease (Childs-Pugh class C)
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights


This trial is studying how disease progression and treatment affects changes in gas exchange and blood flow in people with pulmonary arterial hypertension.

Who is the study for?
This trial is for adults aged 18-75 with Pulmonary Hypertension (PH), specifically those who are newly diagnosed or have started treatment within the last three months. Participants must be able to consent and follow the study schedule, and women of childbearing age need a negative pregnancy test before MRI scans. Those awaiting lung transplants can join too, but not if they have severe liver disease, heart issues, active cancer, sickle cell anemia or conditions preventing MRI use.Check my eligibility
What is being tested?
The trial is testing how a type of imaging called Xenon 129 Magnetic Resonance Imaging (MRI) can show changes in lung function and blood flow in patients with different types of Pulmonary Hypertension. It aims to understand how these images change with disease progression or after starting treatment.See study design
What are the potential side effects?
Since this trial involves MRI scanning using hyperpolarized Xenon gas rather than drug interventions, typical side effects associated with medications may not apply. However, there might be risks related to lying still during the scan or reactions to inhaling Xenon gas.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My pulmonary hypertension symptoms are moderate.
I have been diagnosed with a specific type of high blood pressure in my lungs.
I am on the waiting list for a lung transplant.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have sickle cell anemia.
My liver condition is severe.
I have been diagnosed with sarcoidosis.
My pulmonary hypertension is caused by schistosomiasis.
I have moderate to severe heart disease.
My cancer is currently active.
I can undergo an MRI scan without issues.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Red Blood Cell Signal from Xenon MRI
pulmonary vascular remodeling

Trial Design

2Treatment groups
Experimental Treatment
Group I: following pulmonary arterial hypertension subjectsExperimental Treatment1 Intervention
Following pulmonary arterial hypertension subjects upto 24 months
Group II: end-stage pulmonary hypertension .Experimental Treatment1 Intervention
subjects with end-stage PH that currently on the waitlist for lung transplant

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Pulmonary Hypertension (PH) include phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists (ERAs), and prostacyclin analogs. PDE5 inhibitors increase cyclic GMP levels, leading to vasodilation and reduced pulmonary artery pressure. ERAs block endothelin-1, a potent vasoconstrictor, reducing vascular resistance. Prostacyclin analogs promote vasodilation and inhibit platelet aggregation. These treatments are crucial for PH patients as they improve pulmonary blood flow, enhance oxygenation, and improve quality of life and survival.
Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.Clinical trials in group 3 pulmonary hypertension.Pulmonary hypertension in chronic lung disease and hypoxia.

Find a Location

Who is running the clinical trial?

Bastiaan DriehuysLead Sponsor
14 Previous Clinical Trials
1,021 Total Patients Enrolled
Sudarshan Rajagopal, MD, PhDPrincipal InvestigatorDuke University
4 Previous Clinical Trials
70 Total Patients Enrolled

Media Library

129Xe Hyperpolarized (Gas) Clinical Trial Eligibility Overview. Trial Name: NCT04991454 — Phase 2
Pulmonary Hypertension Research Study Groups: following pulmonary arterial hypertension subjects, end-stage pulmonary hypertension .
Pulmonary Hypertension Clinical Trial 2023: 129Xe Hyperpolarized Highlights & Side Effects. Trial Name: NCT04991454 — Phase 2
129Xe Hyperpolarized (Gas) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04991454 — Phase 2
~25 spots leftby Aug 2026